Tempus AI Inc. Announces New Clinical Study to Advance Cancer Treatment through AI-Powered Data Insights

Reuters

2025/05/14

<a href="https://laohu8.com/S/TEM">Tempus AI</a> Inc. Announces New Clinical Study to Advance Cancer Treatment through AI-Powered Data Insights

Tempus AI Inc. has announced a significant multi-year strategic collaboration with Boehringer Ingelheim to advance its cancer research pipeline. This partnership aims to leverage Tempus' AI-driven platform and extensive de-identified database, which includes molecular, clinical, and imaging data, to bolster Boehringer Ingelheim's efforts in developing new treatments for difficult-to-treat cancers. The collaboration will focus on utilizing real-world patient data to enhance biomarker development, patient stratification, and the discovery of novel drug targets. By combining Boehringer Ingelheim's internal research with Tempus' advanced data analytics, the partnership seeks to accelerate drug discovery and bring innovative cancer treatments to patients more efficiently.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250514765890) on May 14, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535292870"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535292870\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535292870?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535292870","market":"nz","top_or_hot":-1,"title":"Tempus AI Inc. Announces New Clinical Study to Advance Cancer Treatment through AI-Powered Data Insights","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> Inc. Announces New Clinical Study to Advance Cancer Treatment through AI-Powered Data Insights\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tempus AI Inc. has announced a significant multi-year strategic collaboration with Boehringer Ingelheim to advance its cancer research pipeline. This partnership aims to leverage Tempus' AI-driven platform and extensive de-identified database, which includes molecular, clinical, and imaging data, to bolster Boehringer Ingelheim's efforts in developing new treatments for difficult-to-treat cancers. The collaboration will focus on utilizing real-world patient data to enhance biomarker development, patient stratification, and the discovery of novel drug targets. By combining Boehringer Ingelheim's internal research with Tempus' advanced data analytics, the partnership seeks to accelerate drug discovery and bring innovative cancer treatments to patients more efficiently.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250514765890) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempus AI Inc. Announces New Clinical Study to Advance Cancer Treatment through AI-Powered Data Insights</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI Inc. Announces New Clinical Study to Advance Cancer Treatment through AI-Powered Data Insights\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-14 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> Inc. Announces New Clinical Study to Advance Cancer Treatment through AI-Powered Data Insights\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tempus AI Inc. has announced a significant multi-year strategic collaboration with Boehringer Ingelheim to advance its cancer research pipeline. This partnership aims to leverage Tempus' AI-driven platform and extensive de-identified database, which includes molecular, clinical, and imaging data, to bolster Boehringer Ingelheim's efforts in developing new treatments for difficult-to-treat cancers. The collaboration will focus on utilizing real-world patient data to enhance biomarker development, patient stratification, and the discovery of novel drug targets. By combining Boehringer Ingelheim's internal research with Tempus' advanced data analytics, the partnership seeks to accelerate drug discovery and bring innovative cancer treatments to patients more efficiently.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250514765890) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861559042.SGD","symbol_name":"日兴方舟颠覆性创新基金B SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL1hQrgJ:1","article_id":"2535292870","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535292870","pubTimestamp":1747225858,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tempus AI Inc. has announced a significant multi-year strategic collaboration with Boehringer Ingelheim to advance its cancer research pipeline. This partnership aims to leverage Tempus' AI-driven platform and extensive de-identified database, which includes molecular, clinical, and imaging data, to bolster Boehringer Ingelheim's efforts in developing new treatments for difficult-to-treat cancers. The collaboration will focus on utilizing real-world patient data to enhance biomarker development, patient stratification, and the discovery of novel drug targets. By combining Boehringer Ingelheim's internal research with Tempus' advanced data analytics, the partnership seeks to accelerate drug discovery and bring innovative cancer treatments to patients more efficiently.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpose","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4613":"AI应用软件","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4611":"AI医疗","BK4121":"生命科学工具和服务","TEM":"Tempus AI"},"translate_title":"Tempus AI Inc.宣布新的临床研究，通过人工智能驱动的数据洞察推进癌症治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":0.9},"content_text":"Tempus AI Inc. Announces New Clinical Study to Advance Cancer Treatment through AI-Powered Data Insights\n    \n\n        Tempus AI Inc. has announced a significant multi-year strategic collaboration with Boehringer Ingelheim to advance its cancer research pipeline. This partnership aims to leverage Tempus' AI-driven platform and extensive de-identified database, which includes molecular, clinical, and imaging data, to bolster Boehringer Ingelheim's efforts in developing new treatments for difficult-to-treat cancers. The collaboration will focus on utilizing real-world patient data to enhance biomarker development, patient stratification, and the discovery of novel drug targets. By combining Boehringer Ingelheim's internal research with Tempus' advanced data analytics, the partnership seeks to accelerate drug discovery and bring innovative cancer treatments to patients more efficiently.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250514765890) on May 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}